Cutaneous lupus erythematosus
Identifieur interne : 000067 ( Istex/Corpus ); précédent : 000066; suivant : 000068Cutaneous lupus erythematosus
Auteurs : Christopher B. Hansen ; Kevin W. DahleSource :
- Dermatologic Therapy [ 1396-0296 ] ; 2012-03.
English descriptors
- Teeft :
- Acad, Acad dermatol, Acitretin, Acta derm venereol, Actinic keratoses, Antimalarial, Arch dermatol, Arthritis rheum, Azathioprine, Case report, Case reports, Chloroquine, Clin, Clinical presentation, Clobetasol propionate, Common side effects, Complete resolution, Cutaneous, Cutaneous lesions, Cutaneous lupus erythematosus, Cutaneous lupus erythematosus disease area, Cyclophosphamide, Cyclosporine, Dahle, Dapsone, Dermatol, Dermatologic, Dermatologic conditions, Dermatology, Discoid, Discoid lesions, Discoid lupus erythematosus, Dos, Efalizumab, Erythematosus, Etanercept, Good response, Hansen dahle, Hydroxychloroquine, Hypertrophic, Imiquimod, Immunoglobulin, Intravenous, Intravenous immunoglobulin, Isotretinoin, Ivig, Kuhn, Lesion, Lupus, Lupus erythematosus, Lupus erythematosus profundus, Lupus skin disease, Methotrexate, Mofetil, Mycophenolate, Mycophenolate mofetil, Mycophenolate sodium, Peripheral neuropathy, Pimecrolimus, Randomized, Rash, Recalcitrant, Refractory, Refractory subacute cutaneous lupus erythematosus, Remission, Resistant scle, Rheumatoid arthritis, Rituximab, Ruzicka, Scarring, Scle, Severity index, Side effects, Skin lesions, Steroid, Subacute, Subacute cutaneous lupus erythematosus, Subacute lupus erythematosus, Successful treatment, Sunscreen, Systemic, Systemic lupus erythematosus, Tacrolimus, Tacrolimus ointment, Thalidomide, Topical retinoids, Topical steroids, Urticarial vasculitis, Various forms.
Abstract
Cutaneous lupus erythematosus is a heterogeneous autoimmune condition that can significantly impact quality of life. Treatment is focused on reducing clinical inflammation and preventing scarring. The choice of treatment should be guided based on the severity of disease. Mild or localized disease can be treated with sun protection and topical agents. Antimalarials are the initial treatment of choice if systemic therapy is required. Patients with severe or unresponsive disease can also be treated with a number of other immunomodulating or immunosuppressive agents. Clinicians should be aware of their potential adverse effects and appropriate dosing.
Url:
DOI: 10.1111/j.1529-8019.2012.01508.x
Links to Exploration step
ISTEX:4F9D4A36CF81F7690D1B9B3D136F8AAD701FB65ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cutaneous lupus erythematosus</title><author><name sortKey="Hansen, Christopher B" sort="Hansen, Christopher B" uniqKey="Hansen C" first="Christopher B." last="Hansen">Christopher B. Hansen</name><affiliation><mods:affiliation>Department of Dermatology, University of Utah, Utah, Salt Lake City, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: Christopher.hansen@hsc.utah.edu</mods:affiliation></affiliation></author><author><name sortKey="Dahle, Kevin W" sort="Dahle, Kevin W" uniqKey="Dahle K" first="Kevin W." last="Dahle">Kevin W. Dahle</name><affiliation><mods:affiliation>Department of Dermatology, University of Utah, Utah, Salt Lake City, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4F9D4A36CF81F7690D1B9B3D136F8AAD701FB65E</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1111/j.1529-8019.2012.01508.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-NT2KV4X4-N/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000067</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000067</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Cutaneous lupus erythematosus</title><author><name sortKey="Hansen, Christopher B" sort="Hansen, Christopher B" uniqKey="Hansen C" first="Christopher B." last="Hansen">Christopher B. Hansen</name><affiliation><mods:affiliation>Department of Dermatology, University of Utah, Utah, Salt Lake City, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: Christopher.hansen@hsc.utah.edu</mods:affiliation></affiliation></author><author><name sortKey="Dahle, Kevin W" sort="Dahle, Kevin W" uniqKey="Dahle K" first="Kevin W." last="Dahle">Kevin W. Dahle</name><affiliation><mods:affiliation>Department of Dermatology, University of Utah, Utah, Salt Lake City, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Dermatologic Therapy</title><title level="j" type="sub">Management of collagen vascular disease and related disorders</title><title level="j" type="alt">DERMATOLOGIC THERAPY</title><idno type="ISSN">1396-0296</idno><idno type="eISSN">1529-8019</idno><imprint><biblScope unit="vol">25</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="99">99</biblScope><biblScope unit="page" to="111">111</biblScope><biblScope unit="page-count">13</biblScope><date type="published" when="2012-03">2012-03</date></imprint><idno type="ISSN">1396-0296</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1396-0296</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acad</term><term>Acad dermatol</term><term>Acitretin</term><term>Acta derm venereol</term><term>Actinic keratoses</term><term>Antimalarial</term><term>Arch dermatol</term><term>Arthritis rheum</term><term>Azathioprine</term><term>Case report</term><term>Case reports</term><term>Chloroquine</term><term>Clin</term><term>Clinical presentation</term><term>Clobetasol propionate</term><term>Common side effects</term><term>Complete resolution</term><term>Cutaneous</term><term>Cutaneous lesions</term><term>Cutaneous lupus erythematosus</term><term>Cutaneous lupus erythematosus disease area</term><term>Cyclophosphamide</term><term>Cyclosporine</term><term>Dahle</term><term>Dapsone</term><term>Dermatol</term><term>Dermatologic</term><term>Dermatologic conditions</term><term>Dermatology</term><term>Discoid</term><term>Discoid lesions</term><term>Discoid lupus erythematosus</term><term>Dos</term><term>Efalizumab</term><term>Erythematosus</term><term>Etanercept</term><term>Good response</term><term>Hansen dahle</term><term>Hydroxychloroquine</term><term>Hypertrophic</term><term>Imiquimod</term><term>Immunoglobulin</term><term>Intravenous</term><term>Intravenous immunoglobulin</term><term>Isotretinoin</term><term>Ivig</term><term>Kuhn</term><term>Lesion</term><term>Lupus</term><term>Lupus erythematosus</term><term>Lupus erythematosus profundus</term><term>Lupus skin disease</term><term>Methotrexate</term><term>Mofetil</term><term>Mycophenolate</term><term>Mycophenolate mofetil</term><term>Mycophenolate sodium</term><term>Peripheral neuropathy</term><term>Pimecrolimus</term><term>Randomized</term><term>Rash</term><term>Recalcitrant</term><term>Refractory</term><term>Refractory subacute cutaneous lupus erythematosus</term><term>Remission</term><term>Resistant scle</term><term>Rheumatoid arthritis</term><term>Rituximab</term><term>Ruzicka</term><term>Scarring</term><term>Scle</term><term>Severity index</term><term>Side effects</term><term>Skin lesions</term><term>Steroid</term><term>Subacute</term><term>Subacute cutaneous lupus erythematosus</term><term>Subacute lupus erythematosus</term><term>Successful treatment</term><term>Sunscreen</term><term>Systemic</term><term>Systemic lupus erythematosus</term><term>Tacrolimus</term><term>Tacrolimus ointment</term><term>Thalidomide</term><term>Topical retinoids</term><term>Topical steroids</term><term>Urticarial vasculitis</term><term>Various forms</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Cutaneous lupus erythematosus is a heterogeneous autoimmune condition that can significantly impact quality of life. Treatment is focused on reducing clinical inflammation and preventing scarring. The choice of treatment should be guided based on the severity of disease. Mild or localized disease can be treated with sun protection and topical agents. Antimalarials are the initial treatment of choice if systemic therapy is required. Patients with severe or unresponsive disease can also be treated with a number of other immunomodulating or immunosuppressive agents. Clinicians should be aware of their potential adverse effects and appropriate dosing.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>lupus</json:string><json:string>erythematosus</json:string><json:string>cutaneous</json:string><json:string>dermatol</json:string><json:string>scle</json:string><json:string>cutaneous lupus erythematosus</json:string><json:string>antimalarial</json:string><json:string>thalidomide</json:string><json:string>lupus erythematosus</json:string><json:string>subacute</json:string><json:string>dapsone</json:string><json:string>hydroxychloroquine</json:string><json:string>acad</json:string><json:string>azathioprine</json:string><json:string>acad dermatol</json:string><json:string>arch dermatol</json:string><json:string>sunscreen</json:string><json:string>skin lesions</json:string><json:string>side effects</json:string><json:string>cyclosporine</json:string><json:string>randomized</json:string><json:string>tacrolimus</json:string><json:string>ivig</json:string><json:string>mycophenolate</json:string><json:string>successful treatment</json:string><json:string>rituximab</json:string><json:string>cyclophosphamide</json:string><json:string>etanercept</json:string><json:string>clin</json:string><json:string>imiquimod</json:string><json:string>dermatology</json:string><json:string>lesion</json:string><json:string>acitretin</json:string><json:string>methotrexate</json:string><json:string>subacute cutaneous lupus erythematosus</json:string><json:string>hypertrophic</json:string><json:string>pimecrolimus</json:string><json:string>immunoglobulin</json:string><json:string>dermatologic</json:string><json:string>mycophenolate mofetil</json:string><json:string>mofetil</json:string><json:string>chloroquine</json:string><json:string>scarring</json:string><json:string>discoid lupus erythematosus</json:string><json:string>intravenous</json:string><json:string>remission</json:string><json:string>ruzicka</json:string><json:string>isotretinoin</json:string><json:string>dahle</json:string><json:string>efalizumab</json:string><json:string>discoid</json:string><json:string>refractory</json:string><json:string>various forms</json:string><json:string>systemic lupus erythematosus</json:string><json:string>discoid lesions</json:string><json:string>intravenous immunoglobulin</json:string><json:string>steroid</json:string><json:string>systemic</json:string><json:string>topical steroids</json:string><json:string>cutaneous lesions</json:string><json:string>cutaneous lupus erythematosus disease area</json:string><json:string>case report</json:string><json:string>tacrolimus ointment</json:string><json:string>hansen dahle</json:string><json:string>dos</json:string><json:string>kuhn</json:string><json:string>rash</json:string><json:string>topical retinoids</json:string><json:string>complete resolution</json:string><json:string>clobetasol propionate</json:string><json:string>resistant scle</json:string><json:string>lupus erythematosus profundus</json:string><json:string>peripheral neuropathy</json:string><json:string>rheumatoid arthritis</json:string><json:string>actinic keratoses</json:string><json:string>severity index</json:string><json:string>mycophenolate sodium</json:string><json:string>common side effects</json:string><json:string>lupus skin disease</json:string><json:string>clinical presentation</json:string><json:string>arthritis rheum</json:string><json:string>case reports</json:string><json:string>dermatologic conditions</json:string><json:string>good response</json:string><json:string>subacute lupus erythematosus</json:string><json:string>refractory subacute cutaneous lupus erythematosus</json:string><json:string>acta derm venereol</json:string><json:string>urticarial vasculitis</json:string><json:string>recalcitrant</json:string></teeft></keywords><author><json:item><name>Christopher B. Hansen</name><affiliations><json:string>Department of Dermatology, University of Utah, Utah, Salt Lake City, USA</json:string><json:string>E-mail: Christopher.hansen@hsc.utah.edu</json:string></affiliations></json:item><json:item><name>Kevin W. Dahle</name><affiliations><json:string>Department of Dermatology, University of Utah, Utah, Salt Lake City, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>antimalarials</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cutaneous lupus erythematosus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>therapy</value></json:item></subject><articleId><json:string>DTH1508</json:string></articleId><arkIstex>ark:/67375/WNG-NT2KV4X4-N</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Cutaneous lupus erythematosus is a heterogeneous autoimmune condition that can significantly impact quality of life. Treatment is focused on reducing clinical inflammation and preventing scarring. The choice of treatment should be guided based on the severity of disease. Mild or localized disease can be treated with sun protection and topical agents. Antimalarials are the initial treatment of choice if systemic therapy is required. Patients with severe or unresponsive disease can also be treated with a number of other immunomodulating or immunosuppressive agents. Clinicians should be aware of their potential adverse effects and appropriate dosing.</abstract><qualityIndicators><score>8.128</score><pdfWordCount>8042</pdfWordCount><pdfCharCount>52405</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>13</pdfPageCount><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><pdfWordsPerPage>619</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>94</abstractWordCount><abstractCharCount>655</abstractCharCount><keywordCount>3</keywordCount></qualityIndicators><title>Cutaneous lupus erythematosus</title><pmid><json:string>22741931</json:string></pmid><genre><json:string>article</json:string></genre><host><title>Dermatologic Therapy</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1529-8019</json:string></doi><issn><json:string>1396-0296</json:string></issn><eissn><json:string>1529-8019</json:string></eissn><publisherId><json:string>DTH</json:string></publisherId><volume>25</volume><issue>2</issue><pages><first>99</first><last>111</last><total>13</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Original Articles</value></json:item><json:item><value>Original Article</value></json:item></subject></host><namedEntities><unitex><date><json:string>2009</json:string><json:string>2011</json:string><json:string>1950s</json:string><json:string>1992</json:string><json:string>1981</json:string><json:string>2005</json:string><json:string>1986</json:string><json:string>2001</json:string><json:string>2006</json:string><json:string>1998</json:string><json:string>2002</json:string><json:string>2007</json:string><json:string>1999</json:string><json:string>1988</json:string><json:string>1977</json:string><json:string>2012-05-03</json:string><json:string>2008</json:string><json:string>2010</json:string><json:string>1991</json:string><json:string>1985</json:string></date><geogName></geogName><orgName><json:string>Dahle Department of Dermatology, University of Utah, Salt Lake City, Utah, USA ABSTRACT</json:string><json:string>Food and Drug Administration, HHS</json:string><json:string>Department of Dermatology, University of Utah</json:string><json:string>American Academy of Ophthalmology</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Professor</json:string><json:string>Uncommon</json:string><json:string>Goyal</json:string><json:string>Genereau</json:string><json:string>McArdle</json:string><json:string>Singlecase</json:string><json:string>Hanjani</json:string><json:string>Suess</json:string><json:string>Nousari</json:string><json:string>Sticherling</json:string><json:string>Case</json:string><json:string>Baker</json:string></persName><placeName><json:string>United States</json:string><json:string>Teratogenicity</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Uthman et al.</json:string><json:string>Lampropoulos et al.</json:string><json:string>Tzung et al.</json:string><json:string>Obermoser et al.</json:string><json:string>Kuhn et al.</json:string><json:string>Norman et al.</json:string><json:string>Ujiie et al.</json:string><json:string>Madan et al.</json:string><json:string>Barikbin et al.</json:string><json:string>Boehm et al.</json:string><json:string>Shornick et al.</json:string><json:string>Kieu et al.</json:string><json:string>Albrecht et al.</json:string><json:string>Newton et al.</json:string><json:string>Ruzicka et al.</json:string><json:string>Heine et al.</json:string><json:string>Huele et al.</json:string><json:string>Klein et al.</json:string><json:string>Fautrel et al.</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-NT2KV4X4-N</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - dermatology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - dermatology & venereal diseases</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Dermatology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - General Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2012</publicationDate><copyrightDate>2012</copyrightDate><doi><json:string>10.1111/j.1529-8019.2012.01508.x</json:string></doi><id>4F9D4A36CF81F7690D1B9B3D136F8AAD701FB65E</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-NT2KV4X4-N/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-NT2KV4X4-N/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-NT2KV4X4-N/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Cutaneous lupus erythematosus</title><title level="a" type="short">Cutaneous lupus erythematosus</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher ref="https://scientific-publisher.data.istex.fr/ark:/67375/H02-QW5Q88H5-V">Wiley Publishing Ltd</publisher><availability><licence>© 2012 Wiley Periodicals, Inc.</licence></availability><date type="published" when="2012-03"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Cutaneous lupus erythematosus</title><title level="a" type="short">Cutaneous lupus erythematosus</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">Christopher B.</forename><surname>Hansen</surname></persName><affiliation><orgName type="division">Department of Dermatology</orgName><orgName type="institution">University of Utah</orgName><address><settlement>Salt Lake City</settlement><region>Utah</region><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Kevin W.</forename><surname>Dahle</surname></persName><affiliation><orgName type="division">Department of Dermatology</orgName><orgName type="institution">University of Utah</orgName><address><settlement>Salt Lake City</settlement><region>Utah</region><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><idno type="istex">4F9D4A36CF81F7690D1B9B3D136F8AAD701FB65E</idno><idno type="ark">ark:/67375/WNG-NT2KV4X4-N</idno><idno type="DOI">10.1111/j.1529-8019.2012.01508.x</idno><idno type="unit">DTH1508</idno><idno type="toTypesetVersion">file:DTH.DTH1508.pdf</idno></analytic><monogr><title level="j" type="main">Dermatologic Therapy</title><title level="j" type="sub">Management of collagen vascular disease and related disorders</title><title level="j" type="alt">DERMATOLOGIC THERAPY</title><idno type="pISSN">1396-0296</idno><idno type="eISSN">1529-8019</idno><idno type="book-DOI">10.1111/(ISSN)1529-8019</idno><idno type="book-part-DOI">10.1111/dth.2012.25.issue-2</idno><idno type="product">DTH</idno><imprint><biblScope unit="vol">25</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="99">99</biblScope><biblScope unit="page" to="111">111</biblScope><biblScope unit="page-count">13</biblScope><date type="published" when="2012-03"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract style="main"><head>Abstract</head><p>Cutaneous lupus erythematosus is a heterogeneous autoimmune condition that can significantly impact quality of life. Treatment is focused on reducing clinical inflammation and preventing scarring. The choice of treatment should be guided based on the severity of disease. Mild or localized disease can be treated with sun protection and topical agents. Antimalarials are the initial treatment of choice if systemic therapy is required. Patients with severe or unresponsive disease can also be treated with a number of other immunomodulating or immunosuppressive agents. Clinicians should be aware of their potential adverse effects and appropriate dosing.</p></abstract><textClass><keywords><term xml:id="dth1508-kwd-0001">antimalarials</term><term xml:id="dth1508-kwd-0002">cutaneous lupus erythematosus</term><term xml:id="dth1508-kwd-0003">therapy</term></keywords><keywords rend="tocHeading1"><term>Original Articles</term></keywords><keywords rend="articleCategory"><term>Original Article</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-NT2KV4X4-N/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body" wicri:toSee="Element #text"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component type="serialArticle" version="2.0" xml:id="dth1508" xml:lang="en"><header><publicationMeta level="product"><doi origin="wiley">10.1111/(ISSN)1529-8019</doi><issn type="print">1396-0296</issn><issn type="electronic">1529-8019</issn><idGroup><id type="product" value="DTH"></id></idGroup><titleGroup><title sort="DERMATOLOGIC THERAPY" type="main">Dermatologic Therapy</title><title type="short">Dermatol Ther</title></titleGroup></publicationMeta><publicationMeta level="part" position="03102"><doi origin="wiley">10.1111/dth.2012.25.issue-2</doi><titleGroup><title type="specialIssueTitle">Management of collagen vascular disease and related disorders</title></titleGroup><copyright ownership="publisher">© 2012 Blackwell Publishing</copyright><numberingGroup><numbering number="25" type="journalVolume">25</numbering><numbering type="journalIssue">2</numbering></numberingGroup><coverDate startDate="2012-03">March/April 2012</coverDate></publicationMeta><publicationMeta level="unit" position="20" status="forIssue" type="article"><doi>10.1111/j.1529-8019.2012.01508.x</doi><idGroup><id type="unit" value="DTH1508"></id></idGroup><countGroup><count number="13" type="pageTotal"></count></countGroup><titleGroup><title type="tocHeading1">Original Articles</title><title type="articleCategory">Original Article</title></titleGroup><copyright ownership="publisher">© 2012 Wiley Periodicals, Inc.</copyright><eventGroup><event agent="bestset" date="2012-05-03" type="xmlCreated"></event><event type="firstOnline" date="2012-06-14"></event><event type="publishedOnlineFinalForm" date="2012-06-14"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-17"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.3.4 mode:FullText" date="2015-02-25"></event></eventGroup><numberingGroup><numbering type="pageFirst">99</numbering><numbering type="pageLast">111</numbering></numberingGroup><correspondenceTo>Address correspondence and reprint requests to: Christopher B. Hansen, MD, Assistant Professor, Department of Dermatology, University of Utah, 30 North 1900 East, Salt Lake City, UT 84132, or email: <email>Christopher.hansen@hsc.utah.edu</email>.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:DTH.DTH1508.pdf"></link></linkGroup></publicationMeta><contentMeta><titleGroup><title type="short">Cutaneous lupus erythematosus</title><title type="shortAuthors">Hansen & <fc>D</fc>ahle</title><title type="main">Cutaneous lupus erythematosus</title></titleGroup><creators><creator affiliationRef="#dth1508-aff-0001" corresponding="yes" creatorRole="author" xml:id="dth1508-cr-0001"><personName><givenNames>Christopher B.</givenNames><familyName>Hansen</familyName></personName></creator><creator affiliationRef="#dth1508-aff-0001" creatorRole="author" xml:id="dth1508-cr-0002"><personName><givenNames>Kevin W.</givenNames><familyName>Dahle</familyName></personName></creator></creators><affiliationGroup><affiliation countryCode="US" xml:id="dth1508-aff-0001"><orgDiv>Department of Dermatology</orgDiv><orgName>University of Utah</orgName><address><city>Salt Lake City</city><countryPart>Utah</countryPart><country>USA</country></address></affiliation></affiliationGroup><keywordGroup type="author"><keyword xml:id="dth1508-kwd-0001">antimalarials</keyword><keyword xml:id="dth1508-kwd-0002">cutaneous lupus erythematosus</keyword><keyword xml:id="dth1508-kwd-0003">therapy</keyword></keywordGroup><abstractGroup><abstract type="main"><title type="main">Abstract</title><p>Cutaneous lupus erythematosus is a heterogeneous autoimmune condition that can significantly impact quality of life. Treatment is focused on reducing clinical inflammation and preventing scarring. The choice of treatment should be guided based on the severity of disease. Mild or localized disease can be treated with sun protection and topical agents. Antimalarials are the initial treatment of choice if systemic therapy is required. Patients with severe or unresponsive disease can also be treated with a number of other immunomodulating or immunosuppressive agents. Clinicians should be aware of their potential adverse effects and appropriate dosing.</p></abstract></abstractGroup></contentMeta></header> </component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Cutaneous lupus erythematosus</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Cutaneous lupus erythematosus</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">Christopher B.</namePart><namePart type="family">Hansen</namePart><affiliation>Department of Dermatology, University of Utah, Utah, Salt Lake City, USA</affiliation><affiliation>E-mail: Christopher.hansen@hsc.utah.edu</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kevin W.</namePart><namePart type="family">Dahle</namePart><affiliation>Department of Dermatology, University of Utah, Utah, Salt Lake City, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><dateIssued encoding="w3cdtf">2012-03</dateIssued><dateCreated encoding="w3cdtf">2012-05-03</dateCreated><copyrightDate encoding="w3cdtf">2012</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract>Cutaneous lupus erythematosus is a heterogeneous autoimmune condition that can significantly impact quality of life. Treatment is focused on reducing clinical inflammation and preventing scarring. The choice of treatment should be guided based on the severity of disease. Mild or localized disease can be treated with sun protection and topical agents. Antimalarials are the initial treatment of choice if systemic therapy is required. Patients with severe or unresponsive disease can also be treated with a number of other immunomodulating or immunosuppressive agents. Clinicians should be aware of their potential adverse effects and appropriate dosing.</abstract><subject><genre>keywords</genre><topic>antimalarials</topic><topic>cutaneous lupus erythematosus</topic><topic>therapy</topic></subject><relatedItem type="host"><titleInfo><title>Dermatologic Therapy</title></titleInfo><titleInfo type="abbreviated"><title>Dermatol Ther</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Original Articles</topic><topic>Original Article</topic></subject><identifier type="ISSN">1396-0296</identifier><identifier type="eISSN">1529-8019</identifier><identifier type="DOI">10.1111/(ISSN)1529-8019</identifier><identifier type="PublisherID">DTH</identifier><part><date>2012</date><detail type="title"><title>Management of collagen vascular disease and related disorders</title></detail><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>99</start><end>111</end><total>13</total></extent></part></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0001"><titleInfo><title>Quality of life in cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Klein</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Moghadam‐Kia</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Taylor</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Klein R, Moghadam‐Kia S, Taylor L, et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol 2011: 64 (5): 849–858.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>849</start><end>858</end></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>849</start><end>858</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0002"><titleInfo><title>Distinctive cutaneous subsets in the spectrum of lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">JN</namePart><namePart type="family">Gilliam</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RD</namePart><namePart type="family">Sontheimer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981: 4 (4): 471–475.</note><part><date>1981</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>471</start><end>475</end></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>1981</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>471</start><end>475</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0003"><titleInfo><title>Lupus‐specific skin disease</title></titleInfo><name type="personal"><namePart type="given">RD</namePart><namePart type="family">Sontheimer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DP</namePart><namePart type="family">McCauliffe</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book-chapter</genre><relatedItem type="host"><titleInfo><title>Dubois' lupus erythematosus</title></titleInfo><originInfo><publisher>Lippincott Williams & Wilkins</publisher><place><placeTerm type="text">Philadelphia, PA</placeTerm></place></originInfo><part><date>2007</date><extent unit="pages"><start>576</start><end>620</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0004"><titleInfo><title>Histopathologic comparisons of the subsets of lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">MS</namePart><namePart type="family">Jerdan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AF</namePart><namePart type="family">Hood</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GW</namePart><namePart type="family">Moore</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JP</namePart><namePart type="family">Callen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jerdan MS, Hood AF, Moore GW, Callen JP. Histopathologic comparisons of the subsets of lupus erythematosus. Arch Dermatol 1990: 126 (1): 52–55.</note><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>126</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>52</start><end>55</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>126</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>52</start><end>55</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0005"><titleInfo><title>Lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">MI</namePart><namePart type="family">Costner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RD</namePart><namePart type="family">Sontheimer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TL</namePart><namePart type="family">Provost</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book-chapter</genre><relatedItem type="host"><titleInfo><title>Cutaneous manifestations of rheumatic disease</title></titleInfo><originInfo><publisher>Lippincott Williams & Wilkins</publisher><place><placeTerm type="text">Philadelphia, PA</placeTerm></place></originInfo><part><date>2004</date><extent unit="pages"><start>15</start><end>64</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0006"><titleInfo><title>The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Albrecht</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Taylor</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Berlin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005: 125 (5): 889–894.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>125</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>889</start><end>894</end></extent></part><relatedItem type="host"><titleInfo><title>J Invest Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>125</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>889</start><end>894</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0007"><titleInfo><title>Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Kuhn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AM</namePart><namePart type="family">Meuth</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Bein</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kuhn A, Meuth AM, Bein D, et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol 2010: 163 (1): 83–92.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>163</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>83</start><end>92</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>163</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>83</start><end>92</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0008"><titleInfo><title>Phototesting in lupus erythematosus: a 15‐year experience</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Kuhn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Sonntag</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Richter‐Hintz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kuhn A, Sonntag M, Richter‐Hintz D, et al. Phototesting in lupus erythematosus: a 15‐year experience. J Am Acad Dermatol 2001: 45 (1): 86–95.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>86</start><end>95</end></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>86</start><end>95</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0009"><titleInfo><title>Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing photoprovocation test</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Stege</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MA</namePart><namePart type="family">Budde</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Grether‐Beck</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Krutmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stege H, Budde MA, Grether‐Beck S, Krutmann J. Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing photoprovocation test. Photodermatol Photoimmunol Photomed 2000: 16 (6): 256–259.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>256</start><end>259</end></extent></part><relatedItem type="host"><titleInfo><title>Photodermatol Photoimmunol Photomed</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>256</start><end>259</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0010"><titleInfo><title>Use of sunscreens to protect against ultraviolet‐induced lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">Herzinger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Plewig</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Rocken</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Herzinger T, Plewig G, Rocken M. Use of sunscreens to protect against ultraviolet‐induced lupus erythematosus. Arthritis Rheum 2004: 50 (9): 3045–3046.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><detail type="issue"><caption>no.</caption><number>9</number></detail><extent unit="pages"><start>3045</start><end>3046</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><detail type="issue"><caption>no.</caption><number>9</number></detail><extent unit="pages"><start>3045</start><end>3046</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0011"><titleInfo><title>Photoprotective effects of a broad‐spectrum sunscreen in ultraviolet‐induced cutaneous lupus erythematosus: a randomized, vehicle‐controlled, double‐blind study</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Kuhn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Gensch</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Haust</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kuhn A, Gensch K, Haust M, et al. Photoprotective effects of a broad‐spectrum sunscreen in ultraviolet‐induced cutaneous lupus erythematosus: a randomized, vehicle‐controlled, double‐blind study. J Am Acad Dermatol 2011: 64 (1): 37–48.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>37</start><end>48</end></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>37</start><end>48</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0012"><titleInfo><title>Labeling and effectiveness testing; sunscreen products for over‐the‐counter human use. Final rule</title></titleInfo><name type="corporate"><namePart>Food and Drug Administration, HHS</namePart></name><genre>journal-article</genre><note type="citation/reference">Food and Drug Administration, HHS. Labeling and effectiveness testing; sunscreen products for over‐the‐counter human use. Final rule. Fed Regist 2011: 76 (117): 35620–35665.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><detail type="issue"><caption>no.</caption><number>117</number></detail><extent unit="pages"><start>35620</start><end>35665</end></extent></part><relatedItem type="host"><titleInfo><title>Fed Regist</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><detail type="issue"><caption>no.</caption><number>117</number></detail><extent unit="pages"><start>35620</start><end>35665</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0013"><titleInfo><title>Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Cusack</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Danby</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JC</namePart><namePart type="family">Fallon</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cusack C, Danby C, Fallon JC, et al. Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed 2008: 24 (5): 260–267.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>260</start><end>267</end></extent></part><relatedItem type="host"><titleInfo><title>Photodermatol Photoimmunol Photomed</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>260</start><end>267</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0014"><titleInfo><title>Serum 25‐hydroxyvitamin D levels in patients with cutaneous lupus erythematosus in a Mediterranean region</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Cutillas‐Marco</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Morales‐Suarez‐Varela</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Marquina‐Vila</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Grant</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cutillas‐Marco E, Morales‐Suarez‐Varela M, Marquina‐Vila A, Grant W. Serum 25‐hydroxyvitamin D levels in patients with cutaneous lupus erythematosus in a Mediterranean region. Lupus 2010: 19 (7): 810–814.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>810</start><end>814</end></extent></part><relatedItem type="host"><titleInfo><title>Lupus</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>810</start><end>814</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0015"><titleInfo><title>Vitamin D deficiency in patients with cutaneous lupus erythematosus is prevalent throughout the year</title></titleInfo><name type="personal"><namePart type="given">G</namePart><namePart type="family">Heine</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Lahl</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Muller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Worm</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Heine G, Lahl A, Muller C, Worm M. Vitamin D deficiency in patients with cutaneous lupus erythematosus is prevalent throughout the year. Br J Dermatol 2010: 163 (4): 863–865.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>163</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>863</start><end>865</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>163</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>863</start><end>865</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0016"><titleInfo><title>Drugs for discoid lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Jessop</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DA</namePart><namePart type="family">Whitelaw</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FM</namePart><namePart type="family">Delamere</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2009: (4): CD002954.</note><part><date>2009</date><detail type="issue"><caption>no.</caption><number>4</number></detail></part><relatedItem type="host"><titleInfo><title>Cochrane Database Syst Rev</title></titleInfo><part><date>2009</date><detail type="issue"><caption>no.</caption><number>4</number></detail></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0017"><titleInfo><title>Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy</title></titleInfo><name type="personal"><namePart type="given">HH</namePart><namePart type="family">Roenigk Jr</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Martin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Eichorn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JN</namePart><namePart type="family">Gilliam</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Roenigk HH Jr, Martin JS, Eichorn P, Gilliam JN. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis 1980: 25 (3): 281–285.</note><part><date>1980</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>281</start><end>285</end></extent></part><relatedItem type="host"><titleInfo><title>Cutis</title></titleInfo><part><date>1980</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>281</start><end>285</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0018"><titleInfo><title>The use of topical calcineurin inhibitors in lupus erythematosus: an overview</title></titleInfo><name type="personal"><namePart type="given">U</namePart><namePart type="family">Wollina</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Hansel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wollina U, Hansel G. The use of topical calcineurin inhibitors in lupus erythematosus: an overview. J Eur Acad Dermatol Venereol 2008: 22 (1): 1–6.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>1</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>J Eur Acad Dermatol Venereol</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>1</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0019"><titleInfo><title>Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double‐blind, bilateral comparison study</title></titleInfo><name type="personal"><namePart type="given">TY</namePart><namePart type="family">Tzung</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">YS</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HW</namePart><namePart type="family">Chang</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tzung TY, Liu YS, Chang HW. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double‐blind, bilateral comparison study. Br J Dermatol 2007: 156 (1): 191–192.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>156</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>191</start><end>192</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>156</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>191</start><end>192</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0020"><titleInfo><title>Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy‐resistant cutaneous lupus erythematosus: a cohort study</title></titleInfo><name type="personal"><namePart type="given">V</namePart><namePart type="family">Madan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PJ</namePart><namePart type="family">August</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RJ</namePart><namePart type="family">Chalmers</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Madan V, August PJ, Chalmers RJ. Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy‐resistant cutaneous lupus erythematosus: a cohort study. Clin Exp Dermatol 2010: 35 (1): 27–30.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>27</start><end>30</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Exp Dermatol</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>27</start><end>30</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0021"><titleInfo><title>Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Kuhn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Gensch</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Haust</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kuhn A, Gensch K, Haust M, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. J Am Acad Dermatol 2011: 65 (1): 54–64, 64.e1–2.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>54</start><end>64</end></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>54</start><end>64</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0022"><titleInfo><title>Pimecrolimus 1% cream for cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Krueter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Gambichler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Breuckmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Krueter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004: 51 (3): 407–410.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>407</start><end>410</end></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>407</start><end>410</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0023"><titleInfo><title>Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Tlacuilo‐Parra</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Guevara‐Gutierrez</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Gutierrez‐Murillo</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tlacuilo‐Parra A, Guevara‐Gutierrez E, Gutierrez‐Murillo F, et al. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (Oxford) 2005: 44 (12): 1564–1568.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><detail type="issue"><caption>no.</caption><number>12</number></detail><extent unit="pages"><start>1564</start><end>1568</end></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology (Oxford)</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><detail type="issue"><caption>no.</caption><number>12</number></detail><extent unit="pages"><start>1564</start><end>1568</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0024"><titleInfo><title>Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study</title></titleInfo><name type="personal"><namePart type="given">B</namePart><namePart type="family">Barikbin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Givrad</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Yousefi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Eskandari</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Barikbin B, Givrad S, Yousefi M, Eskandari F. Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clin Exp Dermatol 2009: 34 (7): 776–780.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>776</start><end>780</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Exp Dermatol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>776</start><end>780</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0025"><titleInfo><title>Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Gerdsen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Wenzel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Uerlich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Bieber</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Petrow</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gerdsen R, Wenzel J, Uerlich M, Bieber T, Petrow W. Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod. Dermatology 2002: 205 (4): 416–418.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>205</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>416</start><end>418</end></extent></part><relatedItem type="host"><titleInfo><title>Dermatology</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>205</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>416</start><end>418</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0026"><titleInfo><title>A case of generalized discoid lupus erythematosus: successful treatment with imiquimod cream 5%</title></titleInfo><name type="personal"><namePart type="given">U</namePart><namePart type="family">Gul</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Gonul</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SK</namePart><namePart type="family">Cakmak</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Kilic</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Demiriz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gul U, Gonul M, Cakmak SK, Kilic A, Demiriz M. A case of generalized discoid lupus erythematosus: successful treatment with imiquimod cream 5%. Adv Ther 2006: 23 (5): 787–792.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>787</start><end>792</end></extent></part><relatedItem type="host"><titleInfo><title>Adv Ther</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>787</start><end>792</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0027"><titleInfo><title>Development of subacute cutaneous lupus erythematosus associated with the use of imiquimod to treat actinic keratoses</title></titleInfo><name type="personal"><namePart type="given">TJ</namePart><namePart type="family">Burnett</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JC</namePart><namePart type="family">English 3rd</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LK</namePart><namePart type="family">Ferris</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Burnett TJ, English JC 3rd, Ferris LK. Development of subacute cutaneous lupus erythematosus associated with the use of imiquimod to treat actinic keratoses. J Drugs Dermatol 2010: 9 (8): 1022–1024.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>1022</start><end>1024</end></extent></part><relatedItem type="host"><titleInfo><title>J Drugs Dermatol</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>1022</start><end>1024</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0028"><titleInfo><title>Cutaneous lupus treated with topical tretinoin: a case report</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Seiger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Roland</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Goldman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Seiger E, Roland S, Goldman S. Cutaneous lupus treated with topical tretinoin: a case report. Cutis 1991: 47 (5): 351–355.</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>351</start><end>355</end></extent></part><relatedItem type="host"><titleInfo><title>Cutis</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>351</start><end>355</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0029"><titleInfo><title>Treatment of localized discoid lupus erythematosus with tazarotene</title></titleInfo><name type="personal"><namePart type="given">KR</namePart><namePart type="family">Edwards</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WA</namePart><namePart type="family">Burke</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Edwards KR, Burke WA. Treatment of localized discoid lupus erythematosus with tazarotene. J Am Acad Dermatol 1999: 41 (6): 1049–1050.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>1049</start><end>1050</end></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>1049</start><end>1050</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0030"><titleInfo><title>Two cases of refractory discoid lupus erythematosus successfully treated with topical tocoretinate</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Terao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Matsui</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Katayama</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Terao M, Matsui S, Katayama I. Two cases of refractory discoid lupus erythematosus successfully treated with topical tocoretinate. Dermatol Online J 2011: 17 (4): 15.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>15</start></extent></part><relatedItem type="host"><titleInfo><title>Dermatol Online J</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>15</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0031"><titleInfo><title>Ultraviolet‐A1 (340–400 nm) irradiation therapy in systemic lupus erythermatosus</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">McGrath</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Marinez‐Osuna</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FA</namePart><namePart type="family">Lee</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">McGrath H, Marinez‐Osuna P, Lee FA. Ultraviolet‐A1 (340–400 nm) irradiation therapy in systemic lupus erythermatosus. Lupus 1996: 5 (4): 269–274.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>269</start><end>274</end></extent></part><relatedItem type="host"><titleInfo><title>Lupus</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>269</start><end>274</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0032"><titleInfo><title>New concepts in antimalarial use and mode of action in dermatology</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Kalia</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JP</namePart><namePart type="family">Dutz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007: 20 (4): 160–174.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>160</start><end>174</end></extent></part><relatedItem type="host"><titleInfo><title>Dermatol Ther</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>160</start><end>174</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0033"><titleInfo><title>Immunologic concepts of light reactions in lupus erythematosus and polymorphous light eruptions. I. The mechanism of action of hydroxychloroquine</title></titleInfo><name type="personal"><namePart type="given">RS</namePart><namePart type="family">Lester</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TK</namePart><namePart type="family">Burnham</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Fine</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Murray</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lester RS, Burnham TK, Fine G, Murray K. Immunologic concepts of light reactions in lupus erythematosus and polymorphous light eruptions. I. The mechanism of action of hydroxychloroquine. Arch Dermatol 1967: 96 (1): 1–10.</note><part><date>1967</date><detail type="volume"><caption>vol.</caption><number>96</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>1</start><end>10</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>1967</date><detail type="volume"><caption>vol.</caption><number>96</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>1</start><end>10</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0034"><titleInfo><title>Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Costedoat‐Chalumeau</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Z</namePart><namePart type="family">Amoura</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Hulot</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Costedoat‐Chalumeau N, Amoura Z, Hulot JS, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006: 54 (10): 3284–3290.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>3284</start><end>3290</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>3284</start><end>3290</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0035"><titleInfo><title>Antimalarial therapy in SLE</title></titleInfo><name type="personal"><namePart type="given">JG</namePart><namePart type="family">Lanham</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GR</namePart><namePart type="family">Hughes</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lanham JG, Hughes GR. Antimalarial therapy in SLE. Clin Rheum Dis 1982: 8 (1): 279–298.</note><part><date>1982</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>279</start><end>298</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Rheum Dis</title></titleInfo><part><date>1982</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>279</start><end>298</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0036"><titleInfo><title>Treatment of subacute lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">BB</namePart><namePart type="family">Furner</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Furner BB. Treatment of subacute lupus erythematosus. Int J Dermatol 1990: 29 (8): 542–547.</note><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>542</start><end>547</end></extent></part><relatedItem type="host"><titleInfo><title>Int J Dermatol</title></titleInfo><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>542</start><end>547</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0037"><titleInfo><title>Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis</title></titleInfo><name type="personal"><namePart type="given">AY</namePart><namePart type="family">Chang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EW</namePart><namePart type="family">Piette</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KP</namePart><namePart type="family">Foering</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TR</namePart><namePart type="family">Tenhave</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Okawa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">VP</namePart><namePart type="family">Werth</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chang AY, Piette EW, Foering KP, Tenhave TR, Okawa J, Werth VP. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol 2011: 147 (11): 1261–1267.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>147</number></detail><detail type="issue"><caption>no.</caption><number>11</number></detail><extent unit="pages"><start>1261</start><end>1267</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>147</number></detail><detail type="issue"><caption>no.</caption><number>11</number></detail><extent unit="pages"><start>1261</start><end>1267</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0038"><titleInfo><title>American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy</title></titleInfo><name type="personal"><namePart type="given">MF</namePart><namePart type="family">Marmor</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">U</namePart><namePart type="family">Kellner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TY</namePart><namePart type="family">Lai</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Lyons</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WF</namePart><namePart type="family">Mieler</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011: 118 (2): 415–422.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>118</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>415</start><end>422</end></extent></part><relatedItem type="host"><titleInfo><title>Ophthalmology</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>118</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>415</start><end>422</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0039"><titleInfo><title>Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: evolution of a dogma</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Dutz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">VP</namePart><namePart type="family">Werth</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dutz J, Werth VP. Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: evolution of a dogma. J Invest Dermatol 2011: 131 (10): 1968–1970.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>131</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>1968</start><end>1970</end></extent></part><relatedItem type="host"><titleInfo><title>J Invest Dermatol</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>131</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>1968</start><end>1970</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0040"><titleInfo><title>Methotrexate in dermatology</title></titleInfo><name type="personal"><namePart type="given">CA</namePart><namePart type="family">Bangert</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MI</namePart><namePart type="family">Costner</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bangert CA, Costner MI. Methotrexate in dermatology. Dermatol Ther 2007: 20 (4): 216–228.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>216</start><end>228</end></extent></part><relatedItem type="host"><titleInfo><title>Dermatol Ther</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>216</start><end>228</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0041"><titleInfo><title>Methotrexate treatment for refractory subacute cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Kuhn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Specker</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Ruzicka</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Lehmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kuhn A, Specker C, Ruzicka T, Lehmann P. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2002: 46 (4): 600–603.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>600</start><end>603</end></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>600</start><end>603</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0042"><titleInfo><title>Discoid lupus erythematosus: uccessful treatment with oral methotrexate</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Goldstein</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Carey</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Goldstein E, Carey W. Discoid lupus erythematosus: uccessful treatment with oral methotrexate. Arch Dermatol 1994: 130 (7): 938–939.</note><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>130</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>938</start><end>939</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>130</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>938</start><end>939</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0043"><titleInfo><title>Management of cutaneous lupus erythematosus with low‐dose methotrexate: indication for modulation of inflammatory mechanisms</title></titleInfo><name type="personal"><namePart type="given">IB</namePart><namePart type="family">Boehm</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GA</namePart><namePart type="family">Boehm</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Bauer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low‐dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int 1998: 18 (2): 59–62.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>59</start><end>62</end></extent></part><relatedItem type="host"><titleInfo><title>Rheumatol Int</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>59</start><end>62</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0044"><titleInfo><title>Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Wenzel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Brahler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Bauer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Bieber</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Tuting</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wenzel J, Brahler S, Bauer R, Bieber T, Tuting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol 2005: 153 (1): 157–162.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>153</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>157</start><end>162</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>153</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>157</start><end>162</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0045"><titleInfo><title>Methotrexate treatment in cutaneous lupus erythematosus: subcutaneous application is as effective as intravenous administration</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Huber</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Tuting</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Bauer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Bieber</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Wenzel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Huber A, Tuting T, Bauer R, Bieber T, Wenzel J. Methotrexate treatment in cutaneous lupus erythematosus: subcutaneous application is as effective as intravenous administration. Br J Dermatol 2006: 155 (4): 861–862.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>155</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>861</start><end>862</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>155</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>861</start><end>862</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0046"><titleInfo><title>Treatment of cutaneous lupus erythematosus with etretinate</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">Ruzicka</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Meurer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O</namePart><namePart type="family">Braun‐Falco</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ruzicka T, Meurer M, Braun‐Falco O. Treatment of cutaneous lupus erythematosus with etretinate. Acta Derm Venereol 1985: 65 (4): 324–329.</note><part><date>1985</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>324</start><end>329</end></extent></part><relatedItem type="host"><titleInfo><title>Acta Derm Venereol</title></titleInfo><part><date>1985</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>324</start><end>329</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0047"><titleInfo><title>Efficiency of acitretin in the treatment of cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">Ruzicka</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Meurer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Bieber</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ruzicka T, Meurer M, Bieber T. Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Arch Dermatol 1988: 124 (6): 897–902.</note><part><date>1988</date><detail type="volume"><caption>vol.</caption><number>124</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>897</start><end>902</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>1988</date><detail type="volume"><caption>vol.</caption><number>124</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>897</start><end>902</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0048"><titleInfo><title>Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">Ruzicka</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Sommerburg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Goerz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Kind</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Mensing</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992: 127 (5): 513–518.</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>127</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>513</start><end>518</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>127</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>513</start><end>518</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0049"><titleInfo><title>Hypertrophic lupus erythematosus treated successfully with acitretin as monotherapy</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Al‐Mutairi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Rijhwani</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O</namePart><namePart type="family">Nour‐Eldin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Al‐Mutairi N, Rijhwani M, Nour‐Eldin O. Hypertrophic lupus erythematosus treated successfully with acitretin as monotherapy. J Dermatol 2005: 32 (6): 482–486.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>482</start><end>486</end></extent></part><relatedItem type="host"><titleInfo><title>J Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>482</start><end>486</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0050"><titleInfo><title>Mechanism‐oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">RC</namePart><namePart type="family">Newton</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JL</namePart><namePart type="family">Jorizzo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AR</namePart><namePart type="family">Solomon Jr</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Newton RC, Jorizzo JL, Solomon AR Jr, et al. Mechanism‐oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Arch Dermatol 1986: 122 (2): 170–176.</note><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>122</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>170</start><end>176</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>122</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>170</start><end>176</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0051"><titleInfo><title>Isotretinoin for refractory lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">JK</namePart><namePart type="family">Shornick</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Formica</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AL</namePart><namePart type="family">Parke</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shornick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol 1991: 24 (1): 49–52.</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>49</start><end>52</end></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>49</start><end>52</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0052"><titleInfo><title>Dapsone and sulfones in dermatology: overview and update</title></titleInfo><name type="personal"><namePart type="given">YI</namePart><namePart type="family">Zhu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MJ</namePart><namePart type="family">Stiller</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001: 45 (3): 420–434.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>420</start><end>434</end></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>420</start><end>434</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0053"><titleInfo><title>Annular subacute cutaneous lupus erythematosus responsive to dapsone</title></titleInfo><name type="personal"><namePart type="given">LS</namePart><namePart type="family">McCormack</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ML</namePart><namePart type="family">Elgart</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ML</namePart><namePart type="family">Turner</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">McCormack LS, Elgart ML, Turner ML. Annular subacute cutaneous lupus erythematosus responsive to dapsone. J Am Acad Dermatol 1984: 11 (3): 397–401.</note><part><date>1984</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>397</start><end>401</end></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>1984</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>397</start><end>401</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0054"><titleInfo><title>Lupus erythematosus profundus – report of a case treated with dapsone</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Yamada</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Dekio</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Jidoi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Ozasa</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yamada Y, Dekio S, Jidoi J, Ozasa S. Lupus erythematosus profundus – report of a case treated with dapsone. J Dermatol 1989: 16 (5): 379–382.</note><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>379</start><end>382</end></extent></part><relatedItem type="host"><titleInfo><title>J Dermatol</title></titleInfo><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>379</start><end>382</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0055"><titleInfo><title>Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency</title></titleInfo><name type="personal"><namePart type="given">JH</namePart><namePart type="family">Holtman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DH</namePart><namePart type="family">Neustadt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Klein</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JP</namePart><namePart type="family">Callen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Holtman JH, Neustadt DH, Klein J, Callen JP. Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency. J Rheumatol 1990: 17 (9): 1222–1225.</note><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><detail type="issue"><caption>no.</caption><number>9</number></detail><extent unit="pages"><start>1222</start><end>1225</end></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><detail type="issue"><caption>no.</caption><number>9</number></detail><extent unit="pages"><start>1222</start><end>1225</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0056"><titleInfo><title>Dapsone in the treatment of lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">Ruzicka</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Goerz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ruzicka T, Goerz G. Dapsone in the treatment of lupus erythematosus. Br J Dermatol 1981: 104 (1): 53–56.</note><part><date>1981</date><detail type="volume"><caption>vol.</caption><number>104</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>53</start><end>56</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>1981</date><detail type="volume"><caption>vol.</caption><number>104</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>53</start><end>56</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0057"><titleInfo><title>Dapsone and discoid lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">PR</namePart><namePart type="family">Coburn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Shuster</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Coburn PR, Shuster S. Dapsone and discoid lupus erythematosus. Br J Dermatol 1982: 106 (1): 105–106.</note><part><date>1982</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>105</start><end>106</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>1982</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>105</start><end>106</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0058"><titleInfo><title>Dapsone in the treatment of cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Lindskov</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Reymann</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lindskov R, Reymann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica 1986: 172 (4): 214–217.</note><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>172</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>214</start><end>217</end></extent></part><relatedItem type="host"><titleInfo><title>Dermatologica</title></titleInfo><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>172</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>214</start><end>217</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0059"><titleInfo><title>Lupus erythematosus profundus successfully treated with dapsone: review of the literature</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Ujiie</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Shimizu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Ito</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Arita</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Shimizu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ujiie H, Shimizu T, Ito M, Arita K, Shimizu H. Lupus erythematosus profundus successfully treated with dapsone: review of the literature. Arch Dermatol 2006: 142 (3): 399–401.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>142</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>399</start><end>401</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>142</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>399</start><end>401</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0060"><titleInfo><title>Azathioprine: a guide for the management of dermatology patients</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Wise</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JP</namePart><namePart type="family">Callen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wise M, Callen JP. Azathioprine: a guide for the management of dermatology patients. Dermatol Ther 2007: 20 (4): 206–215.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>206</start><end>215</end></extent></part><relatedItem type="host"><titleInfo><title>Dermatol Ther</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>206</start><end>215</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0061"><titleInfo><title>Successful treatment of generalized discoid skin lesions with azathioprine. Its use in a patient with systemic lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">GC</namePart><namePart type="family">Tsokos</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SW</namePart><namePart type="family">Caughman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JH</namePart><namePart type="family">Klippel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tsokos GC, Caughman SW, Klippel JH. Successful treatment of generalized discoid skin lesions with azathioprine. Its use in a patient with systemic lupus erythematosus. Arch Dermatol 1985: 121 (10): 1323–1325.</note><part><date>1985</date><detail type="volume"><caption>vol.</caption><number>121</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>1323</start><end>1325</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>1985</date><detail type="volume"><caption>vol.</caption><number>121</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>1323</start><end>1325</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0062"><titleInfo><title>Successful treatment of generalized discoid skin lesions with azathioprine</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Shehade</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shehade S. Successful treatment of generalized discoid skin lesions with azathioprine. Arch Dermatol 1986: 122 (4): 376–377.</note><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>122</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>376</start><end>377</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>122</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>376</start><end>377</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0063"><titleInfo><title>Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Ashinoff</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">VP</namePart><namePart type="family">Werth</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AG</namePart><namePart type="family">Franks Jr</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ashinoff R, Werth VP, Franks AG Jr. Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. J Am Acad Dermatol 1988: 19 (5 Pt 2): 961–965.</note><part><date>1988</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><detail type="issue"><caption>no.</caption><number>5 Pt 2</number></detail><extent unit="pages"><start>961</start><end>965</end></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>1988</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><detail type="issue"><caption>no.</caption><number>5 Pt 2</number></detail><extent unit="pages"><start>961</start><end>965</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0064"><titleInfo><title>Azathioprine. An effective, corticosteroid‐sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis</title></titleInfo><name type="personal"><namePart type="given">JP</namePart><namePart type="family">Callen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LV</namePart><namePart type="family">Spencer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JB</namePart><namePart type="family">Burruss</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Holtman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine. An effective, corticosteroid‐sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991: 127 (4): 515–522.</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>127</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>515</start><end>522</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>127</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>515</start><end>522</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0065"><titleInfo><title>Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement</title></titleInfo><name type="personal"><namePart type="given">NM</namePart><namePart type="family">Hanjani</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CH</namePart><namePart type="family">Nousari</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hanjani NM, Nousari CH. Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. Arch Dermatol 2002: 138 (12): 1616–1618.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>138</number></detail><detail type="issue"><caption>no.</caption><number>12</number></detail><extent unit="pages"><start>1616</start><end>1618</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>138</number></detail><detail type="issue"><caption>no.</caption><number>12</number></detail><extent unit="pages"><start>1616</start><end>1618</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0066"><titleInfo><title>Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Goyal</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HC</namePart><namePart type="family">Nousari</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Goyal S, Nousari HC. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 2001: 45 (1): 142–144.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>142</start><end>144</end></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>142</start><end>144</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0067"><titleInfo><title>Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil</title></titleInfo><name type="personal"><namePart type="given">CN</namePart><namePart type="family">Pisoni</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Obermoser</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MJ</namePart><namePart type="family">Cuadrado</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pisoni CN, Obermoser G, Cuadrado MJ, et al. Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol 2005: 23 (3): 393–396.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>393</start><end>396</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Exp Rheumatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>393</start><end>396</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0068"><titleInfo><title>Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Kreuter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NS</namePart><namePart type="family">Tomi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SM</namePart><namePart type="family">Weiner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Huger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Altmeyer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Gambichler</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kreuter A, Tomi NS, Weiner SM, Huger M, Altmeyer P, Gambichler T. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol 2007: 156 (6): 1321–1327.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>156</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>1321</start><end>1327</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>156</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>1321</start><end>1327</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0069"><titleInfo><title>Efficacy of mycophenolate mofetil in antimalarial‐resistant cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">B</namePart><namePart type="family">Gammon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Hansen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MI</namePart><namePart type="family">Costner</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarial‐resistant cutaneous lupus erythematosus. J Am Acad Dermatol 2011: 65 (4): 717–721.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>717</start><end>721</end></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>717</start><end>721</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0070"><titleInfo><title>Mycophenolate mofetil and systemic lupus erythematosus: an overview</title></titleInfo><name type="personal"><namePart type="given">CN</namePart><namePart type="family">Pisoni</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Karim</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MJ</namePart><namePart type="family">Cuadrado</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pisoni CN, Karim Y, Cuadrado MJ. Mycophenolate mofetil and systemic lupus erythematosus: an overview. Lupus 2005: 14 (Suppl 1): s9–11.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 1</number></detail><extent unit="pages"><start>s9</start><end>11</end></extent></part><relatedItem type="host"><titleInfo><title>Lupus</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 1</number></detail><extent unit="pages"><start>s9</start><end>11</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0071"><titleInfo><title>Thalidomide: dermatological indications, mechanisms of action and side‐effects</title></titleInfo><name type="personal"><namePart type="given">JJ</namePart><namePart type="family">Wu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DB</namePart><namePart type="family">Huang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KR</namePart><namePart type="family">Pang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Hsu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SK</namePart><namePart type="family">Tyring</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK. Thalidomide: dermatological indications, mechanisms of action and side‐effects. Br J Dermatol 2005: 153 (2): 254–273.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>153</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>254</start><end>273</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>153</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>254</start><end>273</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0072"><titleInfo><title>Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Knop</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Bonsmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Happle</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Knop J, Bonsmann G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 1983: 108 (4): 461–466.</note><part><date>1983</date><detail type="volume"><caption>vol.</caption><number>108</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>461</start><end>466</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>1983</date><detail type="volume"><caption>vol.</caption><number>108</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>461</start><end>466</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0073"><titleInfo><title>Experience with low‐dose thalidomide therapy in chronic discoid lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">KP</namePart><namePart type="family">Kyriakis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GJ</namePart><namePart type="family">Kontochristopoulos</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DN</namePart><namePart type="family">Panteleos</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience with low‐dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol 2000: 39 (3): 218–222.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>218</start><end>222</end></extent></part><relatedItem type="host"><titleInfo><title>Int J Dermatol</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>218</start><end>222</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0074"><titleInfo><title>Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Briani</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Zara</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Rondinone</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Briani C, Zara G, Rondinone R, et al. Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus. Autoimmunity 2005: 38 (7): 549–555.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>549</start><end>555</end></extent></part><relatedItem type="host"><titleInfo><title>Autoimmunity</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>549</start><end>555</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0075"><titleInfo><title>Long‐term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Coelho</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MI</namePart><namePart type="family">Souto</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CR</namePart><namePart type="family">Cardoso</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Coelho A, Souto MI, Cardoso CR, et al. Long‐term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. Lupus 2005: 14 (6): 434–439.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>434</start><end>439</end></extent></part><relatedItem type="host"><titleInfo><title>Lupus</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>434</start><end>439</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0076"><titleInfo><title>Thalidomide treatment for hypertrophic cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Gambini</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Carrera</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Passoni</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Muratori</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Berti</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Caputo</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gambini D, Carrera C, Passoni E, Muratori S, Berti E, Caputo R. Thalidomide treatment for hypertrophic cutaneous lupus erythematosus. J Dermatolog Treat 2004: 15 (6): 365–371.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>365</start><end>371</end></extent></part><relatedItem type="host"><titleInfo><title>J Dermatolog Treat</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>365</start><end>371</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0077"><titleInfo><title>S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide</title></titleInfo><name type="personal"><namePart type="given">JB</namePart><namePart type="family">Zeldis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BA</namePart><namePart type="family">Williams</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SD</namePart><namePart type="family">Thomas</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ME</namePart><namePart type="family">Elsayed</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zeldis JB, Williams BA, Thomas SD, Elsayed ME. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999: 21 (2): 319–330.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>319</start><end>330</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Ther</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>319</start><end>330</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0078"><titleInfo><title>Lenalidomide for the treatment of resistant discoid lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Shah</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Albrecht</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Z</namePart><namePart type="family">Bonilla‐Martinez</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shah A, Albrecht J, Bonilla‐Martinez Z, et al. Lenalidomide for the treatment of resistant discoid lupus erythematosus. Arch Dermatol 2009: 145 (3): 303–306.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>145</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>303</start><end>306</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>145</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>303</start><end>306</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0079"><titleInfo><title>The use of i.v. IG therapy in dermatology</title></titleInfo><name type="personal"><namePart type="given">AP</namePart><namePart type="family">Fernandez</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FA</namePart><namePart type="family">Kerdel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fernandez AP, Kerdel FA. The use of i.v. IG therapy in dermatology. Dermatol Ther 2007: 20 (4): 288–305.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>288</start><end>305</end></extent></part><relatedItem type="host"><titleInfo><title>Dermatol Ther</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>288</start><end>305</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0080"><titleInfo><title>High‐dose intravenous immunoglobulin in cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">Genereau</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O</namePart><namePart type="family">Chosidow</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Danel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Cherin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Herson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Genereau T, Chosidow O, Danel C, Cherin P, Herson S. High‐dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol 1999: 135 (9): 1124–1125.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>135</number></detail><detail type="issue"><caption>no.</caption><number>9</number></detail><extent unit="pages"><start>1124</start><end>1125</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>135</number></detail><detail type="issue"><caption>no.</caption><number>9</number></detail><extent unit="pages"><start>1124</start><end>1125</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0081"><titleInfo><title>Intravenous immunoglobulin (IVIg) for therapy‐resistant cutaneous lupus erythematosus (LE)</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Goodfield</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Davison</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Bowden</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Goodfield M, Davison K, Bowden K. Intravenous immunoglobulin (IVIg) for therapy‐resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat 2004: 15 (1): 46–50.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>46</start><end>50</end></extent></part><relatedItem type="host"><titleInfo><title>J Dermatolog Treat</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>46</start><end>50</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0082"><titleInfo><title>Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Kreuter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Hyun</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Altmeyer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Gambichler</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kreuter A, Hyun J, Altmeyer P, Gambichler T. Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus. Acta Derm Venereol 2005: 85 (6): 545–547.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>545</start><end>547</end></extent></part><relatedItem type="host"><titleInfo><title>Acta Derm Venereol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>545</start><end>547</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0083"><titleInfo><title>Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative</title></titleInfo><name type="personal"><namePart type="given">CE</namePart><namePart type="family">Lampropoulos</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GR</namePart><namePart type="family">Hughes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DP</namePart><namePart type="family">D'Cruz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lampropoulos CE, Hughes GR, D'Cruz DP. Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative. Clin Rheumatol 2007: 26 (6): 981–983.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>981</start><end>983</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Rheumatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>981</start><end>983</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0084"><titleInfo><title>Intravenous immunoglobulin in lupus panniculitis</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Espirito Santo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MF</namePart><namePart type="family">Gomes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MJ</namePart><namePart type="family">Gomes</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Espirito Santo J, Gomes MF, Gomes MJ, et al. Intravenous immunoglobulin in lupus panniculitis. Clin Rev Allergy Immunol 2010: 38 (2–3): 307–318.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><detail type="issue"><caption>no.</caption><number>2–3</number></detail><extent unit="pages"><start>307</start><end>318</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Rev Allergy Immunol</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><detail type="issue"><caption>no.</caption><number>2–3</number></detail><extent unit="pages"><start>307</start><end>318</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0085"><titleInfo><title>Treatment of discoid and subacute lupus erythematosus with cyclophosphamide</title></titleInfo><name type="personal"><namePart type="given">EJ</namePart><namePart type="family">Schulz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MA</namePart><namePart type="family">Menter</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schulz EJ, Menter MA. Treatment of discoid and subacute lupus erythematosus with cyclophosphamide. Br J Dermatol 1971: 85: 60–65.</note><part><date>1971</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>60</start><end>65</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>1971</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>60</start><end>65</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0086"><titleInfo><title>Pulse cyclophosphamide treatment for severe refractory cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Raptopoulou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Linardakis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Sidiropoulos</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HD</namePart><namePart type="family">Kritikos</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DT</namePart><namePart type="family">Boumpas</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Raptopoulou A, Linardakis C, Sidiropoulos P, Kritikos HD, Boumpas DT. Pulse cyclophosphamide treatment for severe refractory cutaneous lupus erythematosus. Lupus 2010: 19 (6): 744–747.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>744</start><end>747</end></extent></part><relatedItem type="host"><titleInfo><title>Lupus</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>744</start><end>747</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0087"><titleInfo><title>Pulse intravenous cyclophosphamide therapy for dermatologic disorders</title></titleInfo><name type="personal"><namePart type="given">LP</namePart><namePart type="family">Fox</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AG</namePart><namePart type="family">Pandya</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fox LP, Pandya AG. Pulse intravenous cyclophosphamide therapy for dermatologic disorders. Dermatol Clin 2000: 18 (3): 459–473.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>459</start><end>473</end></extent></part><relatedItem type="host"><titleInfo><title>Dermatol Clin</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>459</start><end>473</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0088"><titleInfo><title>Systemic ciclosporin and tacrolimus in dermatology</title></titleInfo><name type="personal"><namePart type="given">V</namePart><namePart type="family">Madan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CE</namePart><namePart type="family">Griffiths</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Madan V, Griffiths CE. Systemic ciclosporin and tacrolimus in dermatology. Dermatol Ther 2007: 20 (4): 239–250.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>239</start><end>250</end></extent></part><relatedItem type="host"><titleInfo><title>Dermatol Ther</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>239</start><end>250</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0089"><titleInfo><title>Maintaining remission of lupus erythematosus profundus (LEP) with cyclosporin A</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Saeki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Ohshima</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Kurimoto</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Miura</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Suemura</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Saeki Y, Ohshima S, Kurimoto I, Miura H, Suemura M. Maintaining remission of lupus erythematosus profundus (LEP) with cyclosporin A. Lupus 2000: 9 (5): 390–392.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>390</start><end>392</end></extent></part><relatedItem type="host"><titleInfo><title>Lupus</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>390</start><end>392</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0090"><titleInfo><title>Cyclosporine in the treatment of lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">F</namePart><namePart type="family">Huele</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">van Joost</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Beukers</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Huele F, van Joost T, Beukers R. Cyclosporine in the treatment of lupus erythematosus. Arch Dermatol 1986: 122 (9): 973–974.</note><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>122</number></detail><detail type="issue"><caption>no.</caption><number>9</number></detail><extent unit="pages"><start>973</start><end>974</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>122</number></detail><detail type="issue"><caption>no.</caption><number>9</number></detail><extent unit="pages"><start>973</start><end>974</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0091"><titleInfo><title>Coexisting lichen planus and subacute cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Grabbe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Kolde</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Grabbe S, Kolde G. Coexisting lichen planus and subacute cutaneous lupus erythematosus. Clin Exp Dermatol 1995: 20 (3): 249–254.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>249</start><end>254</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Exp Dermatol</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>249</start><end>254</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0092"><titleInfo><title>Cyclosporin combined with methotrexate in two patients with recalcitrant subacute cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Klein</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Vogt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SM</namePart><namePart type="family">Wenzel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Fleck</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Landthaler</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Klein A, Vogt T, Wenzel SM, Fleck M, Landthaler M. Cyclosporin combined with methotrexate in two patients with recalcitrant subacute cutaneous lupus erythematosus. Australas J Dermatol 2011: 52 (1): 43–47.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>43</start><end>47</end></extent></part><relatedItem type="host"><titleInfo><title>Australas J Dermatol</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>43</start><end>47</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0093"><titleInfo><title>Discoid lupus erythematosus in a patient receiving cyclosporine for liver transplantation</title></titleInfo><name type="personal"><namePart type="given">G</namePart><namePart type="family">Obermoser</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Weber</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Sepp</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Obermoser G, Weber F, Sepp N. Discoid lupus erythematosus in a patient receiving cyclosporine for liver transplantation. Acta Derm Venereol 2001: 81 (4): 319.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>81</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>319</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Derm Venereol</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>81</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>319</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0094"><titleInfo><title>Leflunomide in subacute cutaneous lupus erythematosus – two sides of a coin</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Seuss</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Sticherling</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Seuss A, Sticherling M. Leflunomide in subacute cutaneous lupus erythematosus – two sides of a coin. Int J Dermatol 2008: 47 (1): 83–86.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>83</start><end>86</end></extent></part><relatedItem type="host"><titleInfo><title>Int J Dermatol</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>83</start><end>86</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0095"><titleInfo><title>Case reports of etanercept in inflammatory dermatoses</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Norman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RG</namePart><namePart type="family">Greenberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JM</namePart><namePart type="family">Jackson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol 2006: 54 (3 Suppl. 2): S139–S142.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><detail type="issue"><caption>no.</caption><number>3 Suppl. 2</number></detail><extent unit="pages"><start>S139</start><end>S142</end></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><detail type="issue"><caption>no.</caption><number>3 Suppl. 2</number></detail><extent unit="pages"><start>S139</start><end>S142</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0096"><titleInfo><title>Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha‐blocking agent: comment on the article by Pisetsky and the letter from Aringer et al.</title></titleInfo><name type="personal"><namePart type="given">B</namePart><namePart type="family">Fautrel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V</namePart><namePart type="family">Foltz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Frances</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Bourgeois</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Rozenberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fautrel B, Foltz V, Frances C, Bourgeois P, Rozenberg S. Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha‐blocking agent: comment on the article by Pisetsky and the letter from Aringer et al. Arthritis Rheum 2002: 46 (5): 1408–1409.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>1408</start><end>1409</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>1408</start><end>1409</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0097"><titleInfo><title>Anti‐TNF‐induced lupus</title></titleInfo><name type="personal"><namePart type="given">EL</namePart><namePart type="family">Williams</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Gadola</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CJ</namePart><namePart type="family">Edwards</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Williams EL, Gadola S, Edwards CJ. Anti‐TNF‐induced lupus. Rheumatology (Oxford) 2009: 48 (7): 716–720.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>716</start><end>720</end></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology (Oxford)</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>716</start><end>720</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0098"><titleInfo><title>Etanercept‐induced subacute cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">GS</namePart><namePart type="family">Bleumink</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EJ</namePart><namePart type="family">ter Borg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CG</namePart><namePart type="family">Ramselaar</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BH</namePart><namePart type="family">Ch Stricker</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bleumink GS, ter Borg EJ, Ramselaar CG, Ch Stricker BH. Etanercept‐induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 2001: 40 (11): 1317–1319.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><detail type="issue"><caption>no.</caption><number>11</number></detail><extent unit="pages"><start>1317</start><end>1319</end></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology (Oxford)</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><detail type="issue"><caption>no.</caption><number>11</number></detail><extent unit="pages"><start>1317</start><end>1319</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0099"><titleInfo><title>Therapy‐resistent lupus skin disease successfully treated with rituximab</title></titleInfo><name type="personal"><namePart type="given">AP</namePart><namePart type="family">Risselada</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CG</namePart><namePart type="family">Kallenberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Risselada AP, Kallenberg CG. Therapy‐resistent lupus skin disease successfully treated with rituximab. Rheumatology (Oxford) 2006: 45 (7): 915–916.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>915</start><end>916</end></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology (Oxford)</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>915</start><end>916</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0100"><titleInfo><title>Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case</title></titleInfo><name type="personal"><namePart type="given">I</namePart><namePart type="family">Uthman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Taher</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O</namePart><namePart type="family">Abbas</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Menassa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Ghosn</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Uthman I, Taher A, Abbas O, Menassa J, Ghosn S. Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case. Dermatology 2008: 216 (3): 257–259.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>216</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>257</start><end>259</end></extent></part><relatedItem type="host"><titleInfo><title>Dermatology</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>216</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>257</start><end>259</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0101"><titleInfo><title>Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab</title></titleInfo><name type="personal"><namePart type="given">V</namePart><namePart type="family">Kieu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">O'Brien</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LM</namePart><namePart type="family">Yap</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kieu V, O'Brien T, Yap LM, et al. Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab. Australas J Dermatol 2009: 50 (3): 202–206.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>202</start><end>206</end></extent></part><relatedItem type="host"><titleInfo><title>Australas J Dermatol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>202</start><end>206</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0102"><titleInfo><title>A case of “refractory” lupus erythematosus profundus responsive to rituximab (case report)</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">McArdle</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JF</namePart><namePart type="family">Baker</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">McArdle A, Baker JF. A case of “refractory” lupus erythematosus profundus responsive to rituximab (case report). Clin Rheumatol 2009: 28 (6): 745–746.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>745</start><end>746</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Rheumatol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>745</start><end>746</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0103"><titleInfo><title>Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab</title></titleInfo><name type="personal"><namePart type="given">TH</namePart><namePart type="family">Clayton</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Ogden</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MD</namePart><namePart type="family">Goodfield</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Clayton TH, Ogden S, Goodfield MD. Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab. J Am Acad Dermatol 2006: 54 (5): 892–895.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>892</start><end>895</end></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>892</start><end>895</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0104"><titleInfo><title>Efalizumab in the treatment of discoid lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Usmani</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Goodfield</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Usmani N, Goodfield M. Efalizumab in the treatment of discoid lupus erythematosus. Arch Dermatol 2007: 143 (7): 873–877.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>143</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>873</start><end>877</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>143</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>873</start><end>877</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0105"><titleInfo><title>Efalizumab for subacute cutaneous lupus: report of two different outcomes</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Sanchez‐Cano</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JL</namePart><namePart type="family">Callejas‐Rubio</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Rios‐Fernandez</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MT</namePart><namePart type="family">Gutierrez‐Salmeron</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MA</namePart><namePart type="family">Fernandez Pugnaire</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Ortego‐Centeno</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sanchez‐Cano D, Callejas‐Rubio JL, Rios‐Fernandez R, Gutierrez‐Salmeron MT, Fernandez Pugnaire MA, Ortego‐Centeno N. Efalizumab for subacute cutaneous lupus: report of two different outcomes. Lupus 2009: 18 (14): 1334–1336.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><detail type="issue"><caption>no.</caption><number>14</number></detail><extent unit="pages"><start>1334</start><end>1336</end></extent></part><relatedItem type="host"><titleInfo><title>Lupus</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><detail type="issue"><caption>no.</caption><number>14</number></detail><extent unit="pages"><start>1334</start><end>1336</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0106"><titleInfo><title>IL‐17 in cutaneous lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Tanasescu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Balanescu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Balanescu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tanasescu C, Balanescu E, Balanescu P, et al. IL‐17 in cutaneous lupus erythematosus. Eur J Intern Med 2010: 21 (3): 202–207.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>202</start><end>207</end></extent></part><relatedItem type="host"><titleInfo><title>Eur J Intern Med</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>202</start><end>207</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0107"><titleInfo><title>Successful treatment of subacute lupus erythematosus with ustekinumab</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">De Souza</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Ali‐Shaw</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BE</namePart><namePart type="family">Strober</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AG</namePart><namePart type="family">Franks Jr</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">De Souza A, Ali‐Shaw T, Strober BE, Franks AG Jr. Successful treatment of subacute lupus erythematosus with ustekinumab. Arch Dermatol 2011: 147 (8): 896–898.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>147</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>896</start><end>898</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dermatol</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>147</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>896</start><end>898</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="dth1508-cit-0108"><titleInfo><title>Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo‐controlled, phase 3 trial</title></titleInfo><name type="personal"><namePart type="given">SV</namePart><namePart type="family">Navarra</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RM</namePart><namePart type="family">Guzman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AE</namePart><namePart type="family">Gallacher</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo‐controlled, phase 3 trial. Lancet 2011: 377 (9767): 721–731.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>377</number></detail><detail type="issue"><caption>no.</caption><number>9767</number></detail><extent unit="pages"><start>721</start><end>731</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>377</number></detail><detail type="issue"><caption>no.</caption><number>9767</number></detail><extent unit="pages"><start>721</start><end>731</end></extent></part></relatedItem></relatedItem><identifier type="istex">4F9D4A36CF81F7690D1B9B3D136F8AAD701FB65E</identifier><identifier type="ark">ark:/67375/WNG-NT2KV4X4-N</identifier><identifier type="DOI">10.1111/j.1529-8019.2012.01508.x</identifier><identifier type="ArticleID">DTH1508</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2012 Blackwell Publishing© 2012 Wiley Periodicals, Inc.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-14</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-NT2KV4X4-N/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000067 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000067 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:4F9D4A36CF81F7690D1B9B3D136F8AAD701FB65E
|texte= Cutaneous lupus erythematosus
}}
| This area was generated with Dilib version V0.6.33. |  |